Sullivan IP Solutions

What GSK’s $234 million verdict against Teva teaches us about patent use codes.

Narrow use codes can also lead to failures by generic drug companies to carve-out critical label information.

January 03, 2022

Court reinstates $236 million verdict against Teva for marketing generic version of Coreg® as “AB rated”

October 18, 2020

Generic competition looms for Amarin’s Vascepa (“icosapent ethyl” or “EPA”) capsules in spite of 52 patents listed in FDA’s Orange Book.

June 16, 2020

Despite carve-out of patented indication, claims of induced patent infringement proceed to trial based on skinny label.

May 08, 2017